A pharmacokinetic/pharmacodynamic investigation: Assessment of edivoxetine and atomoxetine on systemic and central 3,4-dihydroxyphenylglycol, a biochemical marker for norepinephrine transporter inhibition

European Neuropsychopharmacology

Volumn 25, Issue 3, 2015, Pages 377-385

  Kielbasa, William ^a   Pan, Alan ^b   Pereira, Alvaro ^c  

^a ELI LILLY AND COMPANY   (United States)

^b GLENEAGLES HOSPITAL   (Singapore)

^c Aepodia SA   (Belgium)

Author keywords

Atomoxetine; DHPG; Edivoxetine; Pharmacodynamics; Pharmacokinetic

Indexed keywords

3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; ATOMOXETINE; EDIVOXETINE; NORADRENALIN TRANSPORTER; PLACEBO; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; ADRENERGIC RECEPTOR AFFECTING AGENT; ALPHA-((5-FLUORO-2-METHOXYPHENYL)METHYL)-ALPHA-(TETRAHYDRO-2H-PYRAN-4-YL)-2-MORPHOLINEMETHANOL; MORPHOLINE DERIVATIVE; PHENETHYL ALCOHOL;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; DRUG HALF LIFE; DYSURIA; EPIDIDYMITIS; HEART PALPITATION; HUMAN; LUMBAR PUNCTURE; MALE; NAUSEA; PHARMACODYNAMICS; PLASMA; PRIORITY JOURNAL; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINE; ANALOGS AND DERIVATIVES; BLOOD; CONTROLLED STUDY; DOSE RESPONSE; ELECTROCHEMICAL ANALYSIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RANDOMIZED CONTROLLED TRIAL; TIME; YOUNG ADULT;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ATOMOXETINE HYDROCHLORIDE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCHEMICAL TECHNIQUES; FEMALE; HUMANS; MALE; METHOXYHYDROXYPHENYLGLYCOL; MORPHOLINES; PHENYLETHYL ALCOHOL; TIME FACTORS; YOUNG ADULT;

EID: 84925943852     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.12.009     Document Type: Article

References (29)

1. Atomoxetine ADHD and Comorbid MDD Study Group, Bangs M.E., Emslie G.J., Spencer T.J., Ramsey J.L., Carlson C., Bartky E.J., Busner J., Duesenberg D.A., Harshawat P., Kaplan S.L., Quintana H., Allen A.J., Sumner C.R. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. J. Child Adolesc. Psychopharmacol. 2007, 17:407-420.
2. Bolden-Watson C., Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 1993, 52:1023-1029.
3. Bymaster F.P., Dreshfield-Ahmad L.J., Threlkeld P.G., Shaw J.L., Thompson L., Nelson D.L., Hemrick-Luecke S.K., Wong D.T. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001, 25:871-880.
4. Bymaster F.P., Katner J.S., Nelson D.L., Hemrick-Luecke S.K., Threlkeld P.G., Heiligenstein J.H., Morin S.M., Gehlert D.R., Perry K.W. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002, 27:699-711.
5. Chappell J.C., Eisenhofer G., Owens M.J., Haber H., Lachno D.R., Dean R.A., Knadler M.P., Nemeroff C.B., Mitchell M.I., Detke M.J., Iyengar S., Pangallo B., Lobo E.D. Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects. J. Clin. Psychopharmacol. 2014, 34:9-16.
6. Dubé S., Dellva M.A., Jones M., Kielbasa W., Padich R., Saha A., Rao P. A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression. J. Psychiatr. Res. 2010, 44:356-363.
7. Eisenhofer G., Goldstein D.S., Kopin I.J. Plasma dihydroxyphenylglycol for estimation of noradrenaline neuronal re-uptake in the sympathetic nervous system in vivo. Clin. Sci. (Lond.) 1989, 76:171-182.
8. Elsworth J.D., Roth R.H., Redmond D.E. Relative importance of 3-methoxy-4-hydroxyphenylglycol and 3,4-dihydroxyphenylglycol as norepinephrine metabolites in rat, monkey, and humans. J. Neurochem. 1983, 41:786-793.
9. Geracioti T.D., Baker D.G., Ekhator N.N., West S.A., Hill K.K., Bruce A.B., Schmidt D., Rounds-Kugler B., Yehuda R., Keck P.E., Kasckow J.W. CSF norepinephrine concentrations in posttraumatic stress disorder. Am. J. Psychiatry 2001, 158:1227-1230.
10. Goldstein D.S., Eisenhofer G., Stull R., Folio C.J., Keiser H.R., Kopin I.J. Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J. Clin. Investig. 1988, 81:213-220.
11. Goldstein D.S., Eisenhofer G., Kopin I.J. Sources and significance of plasma levels of catechols and their metabolites in humans. J. Pharmacol. Exp. Ther. 2003, 305:800-811.
12. Jin L., Xu W., Krefetz D., Gruener D., Kielbasa W., Tauscher-Wisniewski S., Allen A.J. Clinical outcomes from an open-label study of edivoxetine use in pediatric patients with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 2013, 23:200-207.
13. Kielbasa W., Kalvass J.C., Stratford R. Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats. Drug Metab. Dispos. 2009, 37:137-142.
14. Kielbasa, W., Luffer-Atlas, D., Wondmagegnehu, E., Mitchell, M., Turik, M., 2011. Investigation of the potential for PK interactions between edivoxetine, a norepinephrine reuptake inhibitor, and selective serotonin reuptake inhibitor antidepressants in humans. In: Proceedings of the Poster Presented at the Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Dallas, TX, March 2-5.
15. Kielbasa W., Quinlan T., Jin L., Xu W., Lachno D.R., Dean R.A., Allen A.J. Pharmacokinetics and pharmacodynamics of edivoxetine (LY2216684), a norepinephrine reuptake inhibitor, in pediatric patients with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 2012, 22:269-276.
16. Kumagae Y., Matsui Y., Iwata N. Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359. Jpn. J. Pharmacol. 1991, 55:121-128.
17. Lin D.Y., Kratochvil C.J., Xu W., Jin L., D'Souza D.N., Kielbasa W., Allen A.J. A randomized trial of edivoxetine in pediatric patients with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 2014, 24(4):190-200.
18. Martinez J.M., Ball S.G., Marangell L.B., Ferguson M.B., Pangallo B.A., Dellva M.A., Goldberger C., 2014. Edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment: 3 randomized, placebo-controlled, double-blind studies. In: Proceedings of the Poster Presented at the Annual Meeting of the American Society of Clinial Psychopharmacology (ASCP), Hollywood, Florida, June 16-19, 2014. Poster Session 2, Number 44.
19. Michelson D., Faries D., Wernicke J., Kelsey D., Kendrick K., Sallee F.R., Spencer T., Atomoxetine ADHD Study Group Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001, 108:E83.
20. Michelson D., Adler L.A., Amsterdam J.D., Dunner D.L., Nierenberg A.A., Reimherr F.W., Schatzberg A.F., Kelsey D.K., Williams D.W. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 2007, 68:582-587.
21. Pangallo B., Dellva M.A., D'Souza D.N., Essink B., Russell J., Goldberger C. A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder. J. Psychiatr. Res. 2011, 45:748-755.
22. Patil S.T., Higgs R.E., Brandt J.E., Knierman M.D., Gelfanova V., Butler J.P., Downing A.M., Dorocke J., Dean R.A., Potter W.Z., Michelson D., Pan A.X., Jhee S.S., Hale J.E. Identifying pharmacodynamic protein markers of centrally active drugs in humans: a pilot study in a novel clinical model. J. Proteome Res. 2007, 6:955-966.
23. Penttilä J.1, Syvälahti E., Hinkka S., Kuusela T., Scheinin H. The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system. A randomised placebo-controlled study on healthy volunteers. Psychopharmacology (Berl) 2001, 154:343-349.
24. Raskind M.A., Peskind E.R., Holmes C., Goldstein D.S. Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease. Biol. Psychiatry 1999, 46:756-765.
25. Sauer J.M., Ring B.J., Witcher J.W. Clinical pharmacokinetics of atomoxetine. Clin. Pharmacokinet. 2005, 44:571-590.
26. Spencer T., Biederman J., Heiligenstein J., Wilens T., Faries D., Prince J., Faraone S.V., Rea J., Witcher J., Zervas S. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 2001, 11:251-265.
27. Vincent S., Bieck P.R., Garland E.M., Loghin C., Bymaster F.P., Black B.K., Gonzales C., Potter W.Z., Robertson D. Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation 2004, 109:3202-3207.
28. Wong D.T., Threlkeld P.G., Best K.L., Bymaster F.P. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J. Pharmacol. Exp. Ther. 1982, 222:61-65.
29. Zavadil A.P., Ross R.J., Calil H.M., Linnoila M., Blombery P., Jimerson D.C., Kopin I.J., Potter W.Z. The effect of desmethylimipramine on the metabolism of norepinephrine. Life Sci. 1984, 35:1061-1068.